|Bid||151.00 x 1300|
|Ask||153.59 x 900|
|Day's range||151.46 - 153.86|
|52-week range||105.56 - 175.91|
|Beta (5Y monthly)||0.81|
|PE ratio (TTM)||22.07|
|Forward dividend & yield||5.64 (3.67%)|
|Ex-dividend date||14 July 2022|
|1y target est||N/A|
AbbVie kicks off its seventh Week of Possibilities today with approximately 15,000 employees volunteering in more than 50 countries to serve local communities around the world. From June 27 to July 1, AbbVie employees will work with trusted community partners to complete hands-on projects, including renovating schools, playgrounds and community centers, to benefit local communities impacting tens of thousands of people.
AbbVie (NYSE: ABBV) today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of upadacitinib (RINVOQ® 15 mg, once daily) for the treatment of active non-radiographic axial spondyloarthritis (nr‑axSpA) in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAI
AbbVie today shared findings from the newly launched Emotional Impact Report, a survey of more than 300 chronic lymphocytic leukemia (CLL) patients, caregivers and healthcare providers (HCPs), which uncovered insights about the emotional journey associated with a CLL diagnosis.